Stock Trading Canary← United States · Coverage record
US · SEC FORM 4
Bambusa Therapeutics, Inc.
BBTX · — · CIK 0002044950 · Healthcare · Biotechnology
INSIDER SIGNAL
3 buyers · 6 purchase transaction lines · $58.6M gross purchase
WHY THIS SIGNAL?
Score anatomy
Each bar is that part's points in the score; the five parts add up to the score.
What is holding the score back?
- ⚠ Few buyers · 3 insider(s), not 4 or more
- ⚠ Buyers' roles add little · most senior buyer: TenPercentOwner (CEO, chair and 10% owners score lowest)
- ✓ Recent buying · latest purchase 2026-11-02
Average daily trading volume is shown elsewhere on the page as market context; it is not part of the score.
US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.
Insider activity timeline
Owner lanes use transaction dates. Diamonds show later public disclosure dates; the transaction was not public before then. Sales remain context only.
—
Purchase breadth & concentration
Roles in the peak window: Director,TenPercentOwner, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
Latest recorded score
- 79.0
- 78.9
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- —
- 3M
- —
- 6M
- —
- 12M
- —
Volatility & liquidity
- Volatility
- —
- Beta
- —
- Avg daily value
- USD 15.6M
Valuation
- Market cap
- USD 799.7M
- P/E
- —
Fundamentals
- Profit margin
- 0.0%
- ROE
- —
- Industry
- Biotechnology
Market data
Price data up to: 2026-11-05 · Price source: OpenBB/yfinance · From Yahoo Finance: Market cap, Profit margin · Status: PASS
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-10-15 · Captured 2026-11-03 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Disclosure date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|---|
| 2026-11-02 | 2026-11-03 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | Purchase (P) | Common Stock | 2,500,000 | USD 16.00 | USD 40,000,000 | SEC filing ↗ |
| 2026-11-02 | 2026-11-02 | Salvia Investment GmbH | Purchase (P) | Common Stock | 375,000 | USD 16.00 | USD 6,000,000 | SEC filing ↗ |
| 2026-11-02 | 2026-11-02 | Jeggle Helmut Wolfgang | Purchase (P) | Common Stock | 375,000 | USD 16.00 | USD 6,000,000 | SEC filing ↗ |
| 2026-10-30 | 2026-11-03 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | Purchase (P) | Common Stock | 453,820 | USD 14.63 | USD 6,639,957 | SEC filing ↗ |
Form 4 evidence
12 transaction lines in the latest 365-day window; 12 in local history.
| Trade date | Disclosure date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|---|
| 2026-11-02 | 2026-11-03 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | Purchase (P) | Common Stock | 2,500,000 | USD 16.00 | USD 40,000,000 | SEC filing ↗ |
| 2026-11-02 | 2026-11-03 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | C (C) | Common Stock | 4,475,938 | USD — | USD — | SEC filing ↗ |
| 2026-11-02 | 2026-11-02 | Salvia Investment GmbH | Purchase (P) | Common Stock | 375,000 | USD 16.00 | USD 6,000,000 | SEC filing ↗ |
Show recent Form 4 evidence (8 grouped rows)
| Trade date | Disclosure date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|---|
| 2026-11-02 | 2026-11-03 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | Purchase (P) | Common Stock | 2,500,000 | USD 16.00 | USD 40,000,000 | SEC filing ↗ |
| 2026-11-02 | 2026-11-03 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | C (C) | Common Stock | 4,475,938 | USD — | USD — | SEC filing ↗ |
| 2026-11-02 | 2026-11-02 | Salvia Investment GmbH | Purchase (P) | Common Stock | 375,000 | USD 16.00 | USD 6,000,000 | SEC filing ↗ |
| 2026-11-02 | 2026-11-02 | Salvia Investment GmbH | C (C) | Common Stock | 4,769,701 | USD — | USD — | SEC filing ↗ |
| 2026-11-02 | 2026-11-02 | MiNeng, Inc.; Xu Shanshan | C (C) | Common Stock | 163,596 | USD — | USD — | SEC filing ↗ |
| 2026-11-02 | 2026-11-02 | Jeggle Helmut Wolfgang | Purchase (P) | Common Stock | 375,000 | USD 16.00 | USD 6,000,000 | SEC filing ↗ |
| 2026-11-02 | 2026-11-02 | Jeggle Helmut Wolfgang | C (C) | Common Stock | 4,769,701 | USD — | USD — | SEC filing ↗ |
| 2026-10-30 | 2026-11-03 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | Purchase (P) | Common Stock | 453,820 | USD 14.63 | USD 6,639,957 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-11-05 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | REVIEW MAPPING_REVIEW · mapping-review-required |
| Ticker | BBTX |
| CIK | 0002044950 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | — |
Data coverage
| Local Form 4 history | 12 transaction lines from 2026-10-30 to 2026-11-02 6 P purchase lines · 0 S sale lines · 6 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-11-05. Mapping status is an audit field and does not erase SEC filing evidence.